The KIF13A Knockout SK-HEP-1 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population engineered to disrupt the KIF13A gene in the human SK-HEP-1 hepatic adenocarcinoma cell line. This genetically modified pool provides a heterogeneous loss-of-function model that circumvents clonal selection artifacts, enabling robust investigation of KIF13A-dependent processes. The polyclonal format ensures representation of diverse editing outcomes while avoiding the limitations of single-cell-derived clones.
SK-HEP-1 is a widely used human liver adenocarcinoma cell line originally isolated from the ascitic fluid of a patient with liver adenocarcinoma. Notably, these cells exhibit a hybrid phenotype with both mesenchymal and epithelial characteristics, along with endothelial-like properties, making them a valuable model for studying cancer cell plasticity, migration, and metastatic progression. Their derivation from metastatic ascites positions them as a physiologically relevant system for examining the molecular mechanisms driving hepatic tumor dissemination.
KIF13A encodes a plus-end-directed microtubule motor protein that actively transports mannose-6-phosphate receptors (M6PR/IGF2R) from the trans-Golgi network to peripheral endosomes, a process essential for delivering lysosomal hydrolases to lysosomes. KIF13A function is regulated by phosphatidylinositol 3-kinase (PI3K) signaling through its interaction with PI3P lipids, the small GTPase Rab11, and components of the Wnt pathway. The motor directly interacts with the AP-1 adaptor complex and M6PR, facilitating endosomal tubule formation. KIF13A-mediated trafficking influences downstream ??-catenin signaling, as the motor can form complexes with ??-catenin, potentially affecting its nuclear translocation and TCF/LEF-dependent transcription. Consequently, KIF13A sits at the intersection of endosomal dynamics, lysosomal enzyme transport, and Wnt/??-catenin signal transduction.
Disruption of KIF13A in SK-HEP-1 cells is expected to impair M6PR trafficking, leading to mislocalization of lysosomal enzymes and compromised lysosomal function. This defect may alter the degradation and turnover of Wnt pathway components, thereby dysregulating ??-catenin signaling, a pathway frequently hyperactivated in liver cancer. Given the mesenchymal and endothelial features of SK-HEP-1 cells, KIF13A knockout is likely to impact cell migration and invasive properties, offering a relevant platform to dissect the contribution of kinesin-dependent transport to hepatic adenocarcinoma metastasis. The polyclonal pool allows assessment of population-level phenotypic shifts.
This knockout model supports a range of mechanistic and functional studies. Typical applications include examining intracellular transport defects by monitoring M6PR localization via immunofluorescence, assessing lysosomal enzyme activity through biochemical assays, and evaluating Wnt pathway activity using TCF/LEF luciferase reporters. Co-immunoprecipitation experiments can probe KIF13A interactions with ??-catenin or Rab11, while cell migration scratch assays and flow cytometry for surface M6PR enable functional analysis. These cells also facilitate drug screening for kinesin inhibitors targeting metastatic signaling. For further information, please contact Ascent Research.
